<DOC>
	<DOCNO>NCT02808949</DOCNO>
	<brief_summary>Phase 1 PK Study Dapivirine Vaginal Ring Lactating Women .</brief_summary>
	<brief_title>Pharmacokinetic Study Dapivirine Vaginal Ring Lactating Women</brief_title>
	<detailed_description>PK Study Dapivirine Vaginal Ring Lactating Women .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Women must meet follow criterion ( selfreport , unless otherwise indicate ) eligible inclusion study : 1 . Age 18 old screening verify per site SOP 2 . Per participant report , least 6 week postpartum Enrollment 3 . Willing able provide write informed consent screen take part study 4 . Willing able provide adequate locator information , define site SOP 5 . Willing able communicate speak write English 6 . HIV1/2 uninfected Screening Enrollment , per applicable algorithm Appendix II willing receive HIV test result Note : HIV1/2 screening may omit Enrollment time Screening Enrollment &lt; 30 day 7 . Prior Enrollment , breastfeed child stop 8 . Participant intention provide express breast milk child ( ren ) others consumption initiation study product Note : Providing store breast milk child ( ren ) express prior study product exposure exclusionary 9 . Willing able express breast milk least twice daily duration study drug exposure 10 . Per participant report , use effective method contraception Enrollment , intend continue use effective method duration study participation . Effective method MTN029/IPM 039 include : hormonal method ( except contraceptive VRs ) , intrauterine device ( IUD ) insert least 28 day prior enrollment , engage sex exclusively woman , sterilize ( self partner ) , sexually abstinent past 90 day 11 . Women age 21 ( inclusive ) must documentation satisfactory Pap within past 3 year prior Enrollment consistent Grade 0 accord Female Genital Grading Table Use Microbicide Studies ( Addendum 1 DAIDS Table Grading Severity Adult Pediatric Adverse Events , Version 1.0 , November 2007 ) , satisfactory evaluation treatment require Grade 1 high Pap result 12 . At Screening , participant state willingness refrain receptive sexual activity ( include penilevaginal intercourse , anal intercourse , receptive oral intercourse , finger stimulation ) insert nonstudy object vagina ( include tampon , sex toy , female condom , diaphragm , menstrual cup , cervical cap vaginal barrier method , etc . ) , 24 hour prior clinic visit . 13 . At Screening , participant state willingness refrain use vaginal product , include , spermicide , lubricant , contraceptive VRs , douche , vaginal medication , etc. , duration study participation 14 . Per participant report Screening Enrollment , agree participate research study involve drug , medical device , vaginal product , vaccine breast milk sample duration study participation Note : Participation observational study exclusionary Women meet follow criterion ( selfreport , unless otherwise indicate ) exclude study : 1 . Participant report follow : History adverse reaction component dapivirine VR Participation investigational drug device trial within 30 day prior Enrollment Visit ( Day 0 ) Use vaginal medication ( ) 5 day prior Enrollment ( Day 0 ) Complication lactation require treatment , e.g. , mastitis 2 . At time Screening Enrollment , clinical evidence milk supply le 1 ounce per expression 3 . As determined IoR/designee , significant uncontrolled active chronic cardiovascular , renal , liver , hematologic , neurologic , gastrointestinal , psychiatric , endocrine , respiratory , immunologic disorder infectious disease 4 . Grade 2 high AST/ALT Screening Visit : Note : Otherwise eligible participant exclusionary AST/ALT may retested screen process . 5 . Positive urine pregnancy test screen enrollment 6 . Diagnosed urinary tract infection ( UTI ) Screening Enrollment Note : Otherwise eligible participant diagnose UTI screen offer treatment may enrol complete treatment symptom resolve . 7 . Diagnosed STI reproductive tract infection ( RTI ) require treatment per current Centers Disease Control Prevention ( CDC ) guideline Screening Enrollment 8 . On pelvic exam , follow finding : Incomplete postpartum involution uterus Clinically apparent Grade 2 high pelvic exam finding ( observe study staff ) 9 . Use oral and/or vaginal preparation antibiotic antifungal medication within 5 day Enrollment 10 . At Screening Enrollment , social medical condition , investigator 's opinion , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Lactating Women</keyword>
	<keyword>Healthy</keyword>
</DOC>